Navigation Links
Researchers add new tool to tumor-treatment arsenal

A new study demonstrates the potential effectiveness of treating tumors by combining agents that damage DNA with a drug that sensitizes cancer cells to these agents.

The research, led by George Thomas, PhD, professor at the University of Cincinnati's (UC) Genome Research Institute, and Heidi Lane of Novartis Institutes for Biomedical Research, appears in the March 25, 2005, issue of the journal Cell.

Dr. Thomas and a co-author Stefano Fumagalli, PhD, began this research while working at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland, and completed these studies at UC's Genome Research Institute, where further studies continue.

"The use of DNA-damaging agents has revolutionized chemotherapy against a wide variety of cancers," says Dr. Thomas. "However, a narrow therapeutic window, combined with possible severe side effects, has greatly limited their broader use."

These factors, says Dr. Thomas, have probably contributed to recent reports of the under-dosing of patients and the failure to blunt the disease.

When cancer cells are treated with a DNA-damaging agent, a cancer-suppressing gene known as the "guardian of the cell" (a protein called p53) responds by either killing the cell, if the damage is too severe, or allowing the cancer cell to repair the damaged DNA. If the DNA is repaired, cells can continue to multiply.

The dilemma is that high doses of DNA-damaging agents can be toxic, and doses that are too low allow for DNA repair and further cell growth. Thus, says Dr. Thomas, there is need for drugs that can sensitize cells to lower doses of DNA-damaging agents to guarantee cell death, but without the toxic side effects.

The researchers studied the results of combining a DNA-damaging agent called cisplatin with RAD001, a derivative of the immunosuppressive drug rapamycin. Used in organ transplant patients, rapamycin and its derivatives have shown promising anti-tumor activity i n phase I and II clinical trials.

RAD001 lowers the amount of DNA-damaging agent needed by blocking p53's DNA-repair function, automatically killing the cancer cells when agents like cisplatin are introduced.

"These findings provide the rationale for combining DNA-damaging agents with sensitizing agents like RAD001," says Dr. Thomas. "Since about 50 percent of all solid tumors contain p53, such a drug combination could dramatically improve the treatment of solid tumors."


'"/>

Source:University of Cincinnati


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
10. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
11. Researchers develop rapid diagnostic tool for pathogen identification
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2020)... ... 2020 , ... Strategic Directions International (SDi) announced today the ... Science Instrumentation Industry. The report will be released on February 28th. The report ... $70 billion laboratory market for analytical and life science instruments. Special offers are ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... sciences companies and government agencies, announced the recent appointment of Jonathan Horn ... Tunnell, with significant experience assessing, designing, and managing enterprise transformation initiatives, especially ...
(Date:2/6/2020)... NEW YORK (PRWEB) , ... ... ... global, full-service clinical research organization (CRO) specializing in complex interventional medical device ... as Vice President, Regulatory Strategy. In this newly established role, Dorothy oversees ...
Breaking Biology News(10 mins):
(Date:1/24/2020)... ... January 24, 2020 , ... The plastic and reconstructive ... Center in New Jersey epitomize the notion that plastic surgery is much more than ... in popular media. , Over the last 20 years NJ Top Docs, Dr. Andrew ...
(Date:1/23/2020)... ... January 22, 2020 , ... ... in the cosmetic surgery industry at two recent North American investor forums specializing ... the Canaccord Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in ...
(Date:1/22/2020)... DIEGO (PRWEB) , ... January 21, 2020 , ... ... to challenges with the precision of Genome editing. The partners have agreed to ... control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the ...
(Date:1/10/2020)... ... January 09, 2020 , ... Phlexglobal, the leading provider ... of Cunesoft, a move that expands the company’s portfolio of best-of-breed technologies designed ... , Based in Munich, Germany, Cunesoft provides intelligent software and expert services for ...
Breaking Biology Technology: